Open AccessHigh expression of L‐type amino acid transporter 1 as a prognostic marker in bile duct adenocarcinomas
Author(s) -
Yanagisawa Nobuyuki,
Hana Kiyomi,
Nakada Norihiro,
Ichinoe Masaaki,
Koizumi Wasaburo,
Endou Hitoshi,
Okayasu Isao,
Murakumo Yoshiki
Publication year - 2014
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.272
Subject(s) - bile duct , medicine , immunohistochemistry , bile acid , adenocarcinoma , gastroenterology , bile duct cancer , transporter , oncology , cancer research , cancer , biology , gene , biochemistry
Abstract Oncocytic L‐type amino acid transporter ( LAT ) 1 may be a prognostic indicator and target of new molecular therapeutic agents against malignancies. To investigate whether LAT 1 expression influence the outcomes of patients with bile duct cancer, the expression of LAT 1, LAT 2, CD 98, and Ki‐67 was investigated immunohistochemically in 134 surgically resected bile duct adenocarcinomas, including 84 distal extrahepatic bile duct adenocarcinomas, 21 hilar cholangiocarcinomas, 15 intrahepatic cholangiocarcinomas, and 14 ampullary adenocarcinomas. LAT 1 expression was weakly correlated with CD98 expression and Ki‐67 labeling index ( LI ). Kaplan–Meier analysis showed a significant difference in prognosis between patients with bile duct adenocarcinomas having LAT 1‐high and ‐low scores, whereas LAT 2 and CD 98 expression and Ki‐67 LI were not predictive of poor prognosis. Prognosis tended to be worse in patients having tumors with LAT 1‐high/ LAT 2‐low than LAT 1‐low/ LAT 2‐high scores ( P = 0.0686). Multivariable analyses revealed that LAT 1 expression, surgical margin, pT stage were independent prognostic factors. In conclusion, aberrant overexpression of LAT 1 in bile duct adenocarcinoma predicts poor prognosis, suggesting that LAT 1 may be a potential target of anticancer therapy.